Article ID Journal Published Year Pages File Type
8780752 Gynecologic Oncology 2017 5 Pages PDF
Abstract
Tolerability and toxicity of olaparib capsules is similar between women ≥ 65 years and < 65 years of age treated for advanced recurrent ovarian cancer. Use of olaparib should be considered in this patient population.
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Preview
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer
Authors
, , , ,